These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29976656)

  • 1. Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.
    Bellaye PS; Yanagihara T; Granton E; Sato S; Shimbori C; Upagupta C; Imani J; Hambly N; Ask K; Gauldie J; Iglarz M; Kolb M
    Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
    Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
    Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress contributes to the induction and persistence of TGF-β1 induced pulmonary fibrosis.
    Cui Y; Robertson J; Maharaj S; Waldhauser L; Niu J; Wang J; Farkas L; Kolb M; Gauldie J
    Int J Biochem Cell Biol; 2011 Aug; 43(8):1122-33. PubMed ID: 21514399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models.
    Yu W; Guo F; Song X
    Pharm Biol; 2017 Dec; 55(1):450-455. PubMed ID: 27937011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis.
    Shimbori C; Bellaye PS; Xia J; Gauldie J; Ask K; Ramos C; Becerril C; Pardo A; Selman M; Kolb M
    J Pathol; 2016 Oct; 240(2):197-210. PubMed ID: 27425145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Therapy with Pirfenidone plus Prednisolone Ameliorates Paraquat-Induced Pulmonary Fibrosis.
    Rasooli R; Pourgholamhosein F; Kamali Y; Nabipour F; Mandegary A
    Inflammation; 2018 Feb; 41(1):134-142. PubMed ID: 28921394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo.
    Ma Z; Zhao C; Chen Q; Yu C; Zhang H; Zhang Z; Huang W; Shen Z
    Pulm Pharmacol Ther; 2018 Dec; 53():100-106. PubMed ID: 30394340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.
    Cipriani P; Di Benedetto P; Ruscitti P; Verzella D; Fischietti M; Zazzeroni F; Liakouli V; Carubbi F; Berardicurti O; Alesse E; Giacomelli R
    Arthritis Res Ther; 2015 Sep; 17(1):247. PubMed ID: 26357964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
    Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
    BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1.
    Jin J; Togo S; Kadoya K; Tulafu M; Namba Y; Iwai M; Watanabe J; Nagahama K; Okabe T; Hidayat M; Kodama Y; Kitamura H; Ogura T; Kitamura N; Ikeo K; Sasaki S; Tominaga S; Takahashi K
    Respir Res; 2019 Jun; 20(1):119. PubMed ID: 31185973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
    Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
    Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina.
    Tian XL; Yao W; Guo ZJ; Gu L; Zhu YJ
    Chin Med Sci J; 2006 Sep; 21(3):145-51. PubMed ID: 17086734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
    Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
    J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model.
    Jarman ER; Khambata VS; Cope C; Jones P; Roger J; Ye LY; Duggan N; Head D; Pearce A; Press NJ; Bellenie B; Sohal B; Jarai G
    Am J Respir Cell Mol Biol; 2014 Jan; 50(1):158-69. PubMed ID: 23977848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin alleviates bleomycin-induced pulmonary fibrosis in rats.
    Guan R; Zhao X; Wang X; Song N; Guo Y; Yan X; Jiang L; Cheng W; Shen L
    Toxicol Lett; 2016 Nov; 262():161-172. PubMed ID: 27717887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
    Oku H; Shimizu T; Kawabata T; Nagira M; Hikita I; Ueyama A; Matsushima S; Torii M; Arimura A
    Eur J Pharmacol; 2008 Aug; 590(1-3):400-8. PubMed ID: 18598692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.
    Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of pirfenidone in a sheep model of pulmonary fibrosis.
    Dewage SNV; Organ L; Koumoundouros E; Derseh HB; Perera KUE; Samuel CS; Stent AW; Snibson KJ
    Exp Lung Res; 2019; 45(9-10):310-322. PubMed ID: 31762329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats.
    Farkas L; Farkas D; Ask K; Möller A; Gauldie J; Margetts P; Inman M; Kolb M
    J Clin Invest; 2009 May; 119(5):1298-311. PubMed ID: 19381013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.